TNF inhibitor therapy for rheumatoid arthritis (Review)

Ma,Xixi; Xu,Shengqian

doi:10.3892/br.2012.42

TNF inhibitor therapy for rheumatoid arthritis (Review)

Authors:
- Xixi Ma
- Shengqian Xu
View Affiliations

Affiliations: Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, P.R. China
Published online on: November 29, 2012 https://doi.org/10.3892/br.2012.42
Pages: 177-184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotherapy has markedly improved treatment outcomes in rheumatoid arthritis (RA). Tumor necrosis factor (TNF)‑α antagonists, such as infliximab (IFX), etanercept (ETN), adalimumab (ADA), golimumab (GOLI) and certolizumab pegol (CZP) have been widely used for the treatment of RA. IFX provides significant, clinically relevant improvement in physical function and the quality of life, inhibits progressive joint damage and sustains improvement in the signs and symptoms of patients with RA. ETN is effective and safe for patients with RA. Combination therapy with ETN plus methotrexate (MTX) reduces disease activity, decreases total joint score progression, slows the pace of joint destruction and improves function more effectively compared to any of the monotherapies. ADA with or without MTX also relieves the signs and symptoms of RA. CZP and GOLI expand the therapeutic schedule for patients with RA. The TNF‑α inhibitors have similar efficacy, but distinct clinical pharmacokinetic and ‑dynamic properties. The common adverse events of these TNF‑α antagonists include adverse reactions, infections and injection‑site reaction. Additionally, these adverse events are mostly mild or moderate and their incidence is low. Certain patients exhibit a lack of response to anti‑TNF‑α therapies. Some patients may discontinue the initial drug and switch to a second anti‑TNF‑α agent. The shortage of clinical response to one agent may not predict deficiency of response to another. This review mainly addresses the latest developments of these biological agents in the treatment of RA.

View Figures

View References

1	Nanke Y, Kotake S, Akama H and Kamatani N: Alkaline phosphatase in rheumatoid arthritis patients: possible contribution of bone-type ALP to the raised activities of ALP in rheumatoid arthritis patients. Clin Rheumatol. 21:198–202. 2002. View Article : Google Scholar
2	Mikuls TR, Saag KG, Criswell LA, et al: Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women’s Health Study. Ann Rheum Dis. 61:994–999. 2002.PubMed/NCBI
3	Kremer JM, Russell AS, Emery P, et al: Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 70:1826–1830. 2011.PubMed/NCBI
4	Keystone E, Freundlich B, Schiff M, Li J and Hooper M: Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol. 36:522–531. 2009. View Article : Google Scholar : PubMed/NCBI
5	Baumgartner SW, Fleischmann RM, Moreland LW, et al: Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol. 31:1532–1537. 2004.
6	Wiens A, Correr CJ, Venson R, Otuki MF and Pontarolo R: A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int. 30:1063–1070. 2010. View Article : Google Scholar
7	Smolen JS, Han C, Bala M, et al ATTRACT Study Group: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 52:1020–1030. 2005.
8	Gao GH, Li J, Xie HW and Lü Z: Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis. Nan Fang Yi Ke Da Xue Xue Bao. 30:724–726. 2010.(In Chinese).
9	Mathias SD, Colwell HH, Miller DP, et al: Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther. 22:128–139. 2000. View Article : Google Scholar : PubMed/NCBI
10	Breedveld FC, Weisman MH, Kavanaugh AF, et al: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54:26–37. 2006.
11	Fütterer A, Mink K, Luz A, Kosco-Vilbois MH and Pfeffer K: The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity. 9:59–70. 1998.PubMed/NCBI
12	Visvanathan S, Rahman MU, Keystone E, et al: Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther. 12:R2112010. View Article : Google Scholar
13	Kleinert S, Tony HP, Krause A, et al: Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int. 32:2759–2767. 2012. View Article : Google Scholar
14	Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al: The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis. 67:1139–1144. 2008. View Article : Google Scholar : PubMed/NCBI
15	Feldmann M, Elliott MJ, Woody JN and Maini RN: Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol. 64:283–350. 1997. View Article : Google Scholar : PubMed/NCBI
16	St. Clair EW, van der Heijde DM, Smolen JS, et al: Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50:3432–3443. 2004.
17	Maini RN, Breedveld FC, Kalden JR, et al: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50:1051–1065. 2004.
18	Takeuchi T, Miyasaka N, Inoue K, Abe T and Koike T: RISING study: Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 19:478–487. 2009. View Article : Google Scholar
19	Delabaye I and De Keyser F; REMITRACT study group: 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther. 12:R1212010. View Article : Google Scholar : PubMed/NCBI
20	Moreland LW, Baumgartner SW, Schiff MH, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor(p75)-Fc fusion protein. N Engl J Med. 337:141–147. 1997. View Article : Google Scholar : PubMed/NCBI
21	Saag KG, Teng GG, Patkar NM, et al: American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59:762–784. 2008. View Article : Google Scholar : PubMed/NCBI
22	van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al: TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54:1063–1074. 2006.
23	Kavanaugh A, Klareskog L, van der Heijde D, et al: Improvements in clinical response between 12 and 24 weeks in patients with-rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis. 67:1444–1447. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kameda H, Ueki Y, Saito K, et al: Japan Biological Agent Study Integrated Consortium. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol. 20:531–538. 2010. View Article : Google Scholar
25	van der Heijde D, Klareskog L, Landewé R, et al: Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 56:3928–3939. 2007.PubMed/NCBI
26	Genovese MC, Bathon JM, Fleischmann RM, et al: Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 32:1232–1242. 2005.PubMed/NCBI
27	van der Heijde D, Klareskog L, Singh A, et al: Patient-reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis. 65:328–334. 2006.
28	Weinblatt ME, Schiff MH, Ruderman EM, et al: Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 58:1921–1930. 2008. View Article : Google Scholar
29	Johnsen AK, Schiff MH, Mease PJ, et al: Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol. 33:659–664. 2006.PubMed/NCBI
30	van de Putte LB, Atkins C, Malaise M, et al: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease-modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 63:508–516. 2004.PubMed/NCBI
31	Furst DE, Schiff MH, Fleischmann RM, et al: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 30:2563–2571. 2003.
32	Kavanaugh A, Fleischmann RM, Emery P, et al: Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. May 19–2012.(Epub ahead of print).
33	Keystone EC, Kavanaugh AF, Sharp JT, et al: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50:1400–1411. 2004.
34	Keystone EC, Kavanaugh A, Weinblatt ME, Patra K and Pangan AL: Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol. 38:855–862. 2011.PubMed/NCBI
35	Takeuchi T, Tanaka Y, Kaneko Y, et al: Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol. 22:327–338. 2012.
36	Strand V, Rentz AM, Cifaldi MA, et al: Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol. 39:63–72. 2012. View Article : Google Scholar : PubMed/NCBI
37	Keystone EC, Genovese MC, Klareskog L, et al: Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 68:789–796. 2009.
38	Shealy D, Cai A, Staquet K, et al: Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2:428–439. 2010. View Article : Google Scholar : PubMed/NCBI
39	Kay J, Matteson EL, Dasgupta B, et al: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 58:964–975. 2008. View Article : Google Scholar : PubMed/NCBI
40	Weinblatt ME, Bingham CO III, Mendelsohn AM, et al: Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. Jun 1–2012.(Epub ahead of print).
41	Genovese MC, Han C, Keystone EC, et al: Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: Results from the GO-FORWARD Study. J Rheumatol. 39:1185–1191. 2012. View Article : Google Scholar : PubMed/NCBI
42	Tanaka Y, Harigai M, Takeuchi T, et al the GO-FORTH Study Group: Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 71:817–824. 2012. View Article : Google Scholar : PubMed/NCBI
43	Emery P, Fleischmann RM, Moreland LW, et al: Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 60:2272–2283. 2009.
44	Nesbitt A, Fossati G, Bergin M, et al: Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 13:1323–1332. 2007. View Article : Google Scholar : PubMed/NCBI
45	Smolen J, Landewe RB, Mease P, et al: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 68:797–804. 2009. View Article : Google Scholar : PubMed/NCBI
46	Keystone E, Heijde D, Mason D Jr, et al: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58:3319–3329. 2008. View Article : Google Scholar
47	Fleischmann R, Vencovsky J, van Vollenhoven RF, et al: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 68:805–811. 2009. View Article : Google Scholar
48	Keystone EC, Combe B, Smolen J, et al: Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford). 51:1628–1638. 2012.PubMed/NCBI
49	Curtis JR, Chen L, Luijtens K, et al: Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis Rheum. 63:2203–2208. 2011. View Article : Google Scholar : PubMed/NCBI
50	Kekow J, Moots RJ, Emery P, et al: Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. Ann Rheum Dis. 69:222–225. 2010. View Article : Google Scholar
51	Weinblatt ME, Kremer JM, Bankhurst AD, et al: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340:253–259. 1999. View Article : Google Scholar
52	Haraoui B, Cividino A, Stewart J, Guérette B and Keystone EC: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study. BMC Musculoskelet Disord. 12:261–270. 2011. View Article : Google Scholar : PubMed/NCBI
53	Aaltonen KJ, Virkki LM, Malmivaara A, et al: Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 7:e30275. 2012. View Article : Google Scholar : PubMed/NCBI
54	Caporali R, Pallavicini FB, Filippini M, et al: Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev. 8:274–280. 2009. View Article : Google Scholar : PubMed/NCBI
55	Hyrich KL, Lunt M, Watson KD, Symmons DP and Silman AJ; British Society for Rheumatology Biologics Register: Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 56:13–20. 2007. View Article : Google Scholar
56	Hetland ML, Christensen IJ, Tarp U, et al: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 62:22–32. 2010.
57	Singh JA, Christensen R, Wells GA, et al: Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J. 128:309–310. 2010.PubMed/NCBI
58	Fonseca JE, Canhão H, Silva C, et al: Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience. Acta Reumatol Port. 31:247–253. 2006.(In Portuguese).
59	Nam JL, Winthrop KL, van Vollenhoven RF, et al: Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 69:976–986. 2010. View Article : Google Scholar
60	Curtis JR, Xie F, Chen L, et al: The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 70:1401–1406. 2011. View Article : Google Scholar : PubMed/NCBI
61	Singh JA, Wells GA, Christensen R, et al: Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 16:CD0087942011.PubMed/NCBI
62	Hansen KE, Hildebrand JP, Genovese MC, et al: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol. 31:1098–1102. 2004.PubMed/NCBI
63	Furst DE, Gaylis N, Bray V, et al: Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 66:893–899. 2007. View Article : Google Scholar : PubMed/NCBI
64	Wick MC, Ernestam S, Lindblad S, et al: Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 34:353–358. 2005. View Article : Google Scholar
65	Hyrich KL, Lunt M, Dixon WG, Watson KD and Symmons DP; BSR Biologics Register: Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford). 47:1000–1005. 2008. View Article : Google Scholar : PubMed/NCBI
66	Scrivo R, Conti F, Spinelli FR, et al: Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo. 61:107–117. 2009.PubMed/NCBI